Pfizer Inc. (PFE)

US — Healthcare Sector
Peers: GILD  SNY  AMGN  BMY  GSK  SYK  MRK  BSX  CELG-RI  DHR 

Automate Your Wheel Strategy on PFE

With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PFE
  • Rev/Share 11.2283
  • Book/Share 15.6573
  • PB 1.571
  • Debt/Equity 0.6967
  • CurrentRatio 1.1584
  • ROIC 0.1119

 

  • MktCap 139352842755.0
  • FreeCF/Share 2.1879
  • PFCF 11.2038
  • PE 12.9582
  • Debt/Assets 0.2998
  • DivYield 0.0698
  • ROE 0.1196

 

  • Rating A
  • Score 4
  • Recommendation Buy
  • P/E Score 3
  • DCF Score 5
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation PFE Cantor Fitzgerald -- Neutral -- $24 April 22, 2025
Resumed PFE BofA Securities -- Neutral -- $29 Dec. 10, 2024
Initiation PFE Bernstein -- Market Perform -- $32 Oct. 17, 2024

News

My Top 3 Pharma Stocks
AKRO, BMY, ETNB, LLY, MRK, NVO, PFE, RHHBY, SPY
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive

Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.

Read More
image for news My Top 3 Pharma Stocks
Pfizer's Q3 Non-Oncology Performance: Here's What to Expect
PFE
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.

Read More
image for news Pfizer's Q3 Non-Oncology Performance: Here's What to Expect
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
LLY, PFE
Published: October 17, 2025 by: Benzinga
Sentiment: Negative

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare valuations from Eli Lilly And Co (NYSE:LLY) to Pfizer Inc (NYSE:PFE).

Read More
image for news Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
What's Behind The Slump In Pfizer Stock?
PFE
Published: October 17, 2025 by: Forbes
Sentiment: Negative

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around $138 billion.

Read More
image for news What's Behind The Slump In Pfizer Stock?
CEOs of Wells Fargo and Pfizer caution the U.S. could lose its edge to China without innovation
PFE
Published: October 15, 2025 by: CNBC
Sentiment: Negative

Wells Fargo CEO Charlie Scharf said AI is boosting productivity but will likely reduce workforce size. Pfizer CEO Albert Bourla warned China is closing the biotech and pharmaceutical patent gap rapidly and said the U.S. needs to focus on innovation.

Read More
image for news CEOs of Wells Fargo and Pfizer caution the U.S. could lose its edge to China without innovation
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
NVO, PFE, RHHBY
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.

Read More
image for news Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
Top Dividend Stocks Delivering Over 5% for True Financial Freedom
O, PFE, UPS, VZ
Published: October 14, 2025 by: 24/7 Wall Street
Sentiment: Positive

It is possible to achieve financial freedom through stock investing. If you pick the right companies, stay invested for the long term, and reinvest the dividends, you can build a solid portfolio for retirement.

Read More
image for news Top Dividend Stocks Delivering Over 5% for True Financial Freedom
3 Sizzling Ultra-High-Yield Stocks Under $50 With Upside Potential
DIN, PFE, WEN
Published: October 14, 2025 by: 24/7 Wall Street
Sentiment: Neutral

Investors can have their higher yields and capital appreciation potential, too. But, of course, there are always added risks to consider, and when it comes to the hard-hit higher-yielders out there, the fundamentals and growth narrative have taken a turn for the worse.

Read More
image for news 3 Sizzling Ultra-High-Yield Stocks Under $50 With Upside Potential
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
PFE
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)
PFE
Published: October 10, 2025 by: Seeking Alpha
Sentiment: Positive

Pfizer's stock is poised for recovery, driven by recent corporate news and a three-year reprieve on drug-import tariffs from the Trump administration, strengthening the bullish case despite prior market reactions. Upcoming Q3 earnings on November 4, 2025, are expected to provide clarity on oncology progress and the impact of the Trump administration's tariff decision, potentially leading to meaningful earnings revisions. Pfizer's deal with TrumpRx, offering drug discounts and committing $70 billion in U.S. manufacturing/R&D, reduces regulatory uncertainty and should attract new investors as guidance is met.

Read More
image for news Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)
Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings
PFE
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive

Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.

Read More
image for news Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings
Life sciences sentiment rises as Pfizer deal eases tariff concerns
PFE
Published: October 07, 2025 by: Proactive Investors
Sentiment: Positive

Sentiment towards life sciences tools and diagnostics firms in North America is turning positive after an agreement between the Trump Administration and Pfizer Inc (NYSE:PFE, ETR:PFE) has significantly eased the uncertainty around Most Favored Nation (MFN) tariffs on pharmaceuticals and related products, Citi analysts have highlighted. Under the deal announced late last month, Pfizer agreed to lower drug prices for Medicaid, sell discounted medicines directly to Americans, make significant investments in the US, and avoid tariffs for three years.

Read More
image for news Life sciences sentiment rises as Pfizer deal eases tariff concerns
Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
JNJ, LLY, PFE
Published: October 06, 2025 by: MarketBeat
Sentiment: Neutral

When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.

Read More
image for news Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
My Top 5 Biotech Stocks Big Pharma Could Buy Next
ABBV, ALVO, AMGN, ARKG, AZN, BIIB, BMY, CSLLY, GILD, GRFS, GSK, IBB, INCY, JNJ, KMDA, LEGN, LLY, MRK, NVS, PFE, PHAT, RDY, REGN, RHHBY, SDZNY
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

Read More
image for news My Top 5 Biotech Stocks Big Pharma Could Buy Next
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
PFE
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Read More
image for news Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
3 Stocks Yielding 5% and More to Buy and Hold for the Next 5 Years
ET, O, PFE
Published: October 06, 2025 by: 24/7 Wall Street
Sentiment: Positive

Read More
image for news 3 Stocks Yielding 5% and More to Buy and Hold for the Next 5 Years
3 High-Yield Dividend Stocks to Buy in October
EPD, PFE, UPS
Published: October 06, 2025 by: 24/7 Wall Street
Sentiment: Positive

To investors, the stock market is considered one of if not the greatest ways to build wealth.

Read More
image for news 3 High-Yield Dividend Stocks to Buy in October
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
NVS, PFE
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Read More
image for news These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?
PFE
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive

Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.

Read More
image for news Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?
The drug price deal between Pfizer and the Trump administration was built on down-to-the-wire team negotiations, building on a relationship between CEO Albert Bourla and President Trump
PFE
Published: October 02, 2025 by: WSJ
Sentiment: Neutral

Down-to-the wire team negotiations capped a long dance between President Trump and CEO Albert Bourla.

Read More
image for news The drug price deal between Pfizer and the Trump administration was built on down-to-the-wire team negotiations, building on a relationship between CEO Albert Bourla and President Trump
All Cap Investing With Kirk Spano
AAPL, ASTS, DIA, F, GLD, GOOG, GOOGL, META, MSFT, NVDA, PFE, PLTR, QQQ, RKLB, SPY, TSLA
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Neutral

Kirk Spano runs Margin of Safety Investing and shares what this moment means for all cap investors. Stock picking and options strategies like covered calls and cash-secured puts to generate income and manage risk.

Read More
image for news All Cap Investing With Kirk Spano
This 6.75%-Yielding Dividend Stock Can Gain 33%
PFE
Published: October 01, 2025 by: 24/7 Wall Street
Sentiment: Positive

Pfizer (NYSE:PFE) shares are finally starting to attract attention after gaining close to 7% in a single trading session on news that it's reached a pricing deal with the Trump administration.

Read More
image for news This 6.75%-Yielding Dividend Stock Can Gain 33%
Pfizer Drug-Pricing Deal: More Upside For PFE Stock?
PFE
Published: October 01, 2025 by: Forbes
Sentiment: Positive

Pfizer stock (NYSE: PFE) offers a compelling investment opportunity at its current price of around $25, supported by attractive valuations and recent policy changes that may present further upside potential.

Read More
image for news Pfizer Drug-Pricing Deal: More Upside For PFE Stock?
Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug
MTSR, PFE
Published: September 30, 2025 by: CNBC
Sentiment: Positive

Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.

Read More
image for news Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug
3 Pharma Stocks Getting an Intraday Trump Bump
BMY, MRK, PFE
Published: September 30, 2025 by: Schaeffers Research
Sentiment: Positive

Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed "TrumpRX.

Read More
image for news 3 Pharma Stocks Getting an Intraday Trump Bump
Pfizer found a way to boost its ailing stock — agree with Trump on drug pricing
PFE
Published: September 30, 2025 by: Market Watch
Sentiment: Positive

Pfizer's stock surged after CEO Albert Bourla announces an agreement with the Trump administration aimed at lowering drug prices in the U.S. and removing tariff uncertainty.

Read More
image for news Pfizer found a way to boost its ailing stock — agree with Trump on drug pricing
What Pfizer's lower drug price agreement may mean for the company
PFE
Published: September 30, 2025 by: CNBC Television
Sentiment: Neutral

CNBC's Angelica Peebles joins "The Exchange" to detail Pfizer's agreement with the Trump administration to voluntarily sell its medications at lower prices in the United States.

Read More
image for news What Pfizer's lower drug price agreement may mean for the company
Pfizer CEO: 'The big winner of this deal clearly will be the American patient'
PFE
Published: September 30, 2025 by: CNBC Television
Sentiment: Positive

Pfizer CEO Albert Bourla, speaking in the Oval Office on Tuesday about the company's deal to lower drug prices, said the winner of the deal will "clearly will be the American patient." Bourla said the company satisfied all four of the requests President Trump outlined.

Read More
image for news Pfizer CEO: 'The big winner of this deal clearly will be the American patient'
Top Stock Movers Now: Spotify, Pfizer, CoreWeave, Lamb Weston, and More
CRWV, LW, PFE, SPOT
Published: September 30, 2025 by: Investopedia
Sentiment: Negative

Major U.S. equities indexes edged lower Tuesday afternoon, as a potential government shutdown loomed. The Dow, S&P 500, and Nasdaq were all slightly lower.

Read More
image for news Top Stock Movers Now: Spotify, Pfizer, CoreWeave, Lamb Weston, and More
US drugmakers rise after Trump announces Pfizer price cuts, promises more deals
PFE
Published: September 30, 2025 by: Reuters
Sentiment: Positive

Shares of Pfizer rose about 5% after U.S. President Donald Trump said on Tuesday the drugmaker will cut the price on all of its prescription drugs sold to the Medicaid insurance program and will introduce all new prescription drugs at a "most favored nation" price.

Read More
image for news US drugmakers rise after Trump announces Pfizer price cuts, promises more deals

About Pfizer Inc. (PFE)

  • IPO Date 1972-06-01
  • Website https://www.pfizer.com
  • Industry Drug Manufacturers - General
  • CEO Albert Bourla
  • Employees 81000

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.